Modality
Cell Therapy
MOA
Anti-Aβ
Target
CD38
Pathway
JAK/STAT
Prostate CaACC
Development Pipeline
Preclinical
Feb 2022
→ Jun 2027
PreclinicalCurrent
NCT03335486
328 pts·ACC
2022-02→2027-06·Active
328 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-231.2y awayInterim· ACC
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Preclinical
Active
Catalysts
Interim
2027-06-23 · 1.2y away
ACC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03335486 | Preclinical | ACC | Active | 328 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |